Add BrightSurf on Google Email

Family Heart Foundation announces results of real-world study in 273,770 individuals with cardiovascular disease demonstrating that risk of subsequent cardiovascular event increases with rising lipoprotein(a) levels

A study of 273,770 individuals with cardiovascular disease found that increasing lipoprotein(a) levels significantly increases the risk of subsequent cardiovascular events. Treatment with high-impact LDL-C lowering therapies may help reduce this risk.

SourceFamily Heart Foundation·JournalEuropean Heart Journal·TypeData/statistical analysis·DateMay 7, 2025

Scientists at the Lewis Katz School of Medicine at Temple University uncover how tau protein weakens the brain’s vascular defenses in Alzheimer’s disease

A harmful form of tau protein directly damages blood vessels in the brain, leading to inflammation and weakening the brain's protective shield. The discovery highlights the importance of focusing on early neurovascular changes mediated by tau to prevent or slow down damage to the blood-brain barrier.

SourceTemple University Health System·JournalAlzheimer s & Dementia·DateApr 29, 2025

Weight loss protects – even when weight is regained

A Swedish study of over 1,300 participants found that losing a significant amount of weight still offers protection against health issues like cancer and cardiovascular disease, even if some weight is regained. However, regaining weight can increase the risk of microvascular disease and other health problems.

SourceUniversity of Gothenburg·JournalThe Lancet Regional Health - Europe·TypeObservational study·DateMar 21, 2025

Security veins: Advanced biometric authentication through AI and infrared

A new method of biometric authentication has been developed using hyperspectral imaging and AI to identify individuals through the unique patterns in their blood vessels on the palm of their hand. The technology shows great promise for secure personal identification and could potentially be used as a key to unlock homes.

SourceOsaka Metropolitan University·JournalJournal of Biomedical Optics·TypeImaging analysis·DateMar 7, 2025

Stem cell transplant clears clinical safety hurdle for the treatment of wet age-related macular degeneration

A new stem cell transplant treatment has shown promising results in clearing clinical safety hurdles for the treatment of wet age-related macular degeneration. The treatment involves removing abnormal blood vessels and transplanting stem cell-derived retinal cells to replace damaged or lost retinal cells.

SourceInternational Society for Stem Cell Research·JournalStem Cell Reports·DateFeb 27, 2025

A new approach to detecting Alzheimer’s disease

Researchers at Lancaster University have developed a new method to detect Alzheimer's disease by analyzing changes in brain oxygenation dynamics and neuronal function. The study found that individuals with Alzheimer's disease exhibit altered respiratory frequency, which may be an early indicator of the condition.

SourceLancaster University·JournalBrain Communications·TypeExperimental study·DateFeb 2, 2025

Tumor-secreted protein may hold the key to better treatments for deadly brain tumor, study finds

A study suggests targeting endocan, a protein produced by endothelial cells in blood vessels, could slow tumor growth and make glioblastoma more vulnerable to existing treatments. The discovery may lead to new strategies to combat glioblastoma, which has an average lifespan of just 12-15 months.

Poor vascular health accelerates brain ageing

Researchers at Karolinska Institutet used AI to analyze brain images from 70-year-olds and found that factors like inflammation and high glucose levels are associated with an older-looking brain. A healthy lifestyle, on the other hand, was linked to brains with a younger appearance.

SourceKarolinska Institutet·JournalAlzheimer s & Dementia·TypeObservational study·DateDec 20, 2024

Study supports new blood-based biomarker to detect early brain changes leading to cognitive impairment and dementia

A new blood-based biomarker, placental growth factor (PlGF), has been identified as a potential tool for detecting early brain changes associated with cognitive impairment and dementia. Elevated PlGF levels were found to be linked to increased vascular permeability, leading to white matter injury and subsequent cognitive decline.

New insights into blood vessel formation

Research team at the University of Basel uncovers new mechanisms in blood vessel formation, highlighting the critical role of dynamic forces and protein regulation. The study reveals that contraction forces enable continuous vascular lumen formation, while Rasip1 plays a key role in initial steps of lumen formation.

SourceUniversity of Basel·JournalNature Communications·DateDec 17, 2024

Caffeine is a heart-healthy habit

Researchers found that patients who consumed caffeine had better vascular health, as measured through endothelial cells. The study suggests that caffeine may play a role in controlling disease progression and improving cardiovascular health.

SourceOxford University Press USA·JournalRheumatology·TypeObservational study·DateOct 9, 2024

Lifesaving star

A novel, star-shaped polymer has been developed as a low-volume resuscitant for prehospital treatment of severe hemorrhagic shock. The solution can refill blood vessels without disrupting coagulation, offering an improvement over existing colloidal resuscitants.

SourceWiley·JournalAngewandte Chemie International Edition·TypeExperimental study·DateJul 3, 2024

A new target for treatment of one type of macular degeneration

Researchers found that inhibiting telomerase, an enzyme related to cell growth and division, can suppress abnormal vascular growth in the retina. This discovery provides a potential alternative treatment option for wet AMD, which is currently treated with anti-VEGF injections.

SourceOhio State University·JournalBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·TypeExperimental study·DateJul 2, 2024

Repurposed drug may help stabilize vision in rare disease

Researchers find that a repurposed drug, crizanlizumab, stabilizes vision in patients with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) after two years of treatment. The study suggests that this may give patients additional years to read, drive, and enjoy activities.

SourceWashU Medicine·JournalJournal of Clinical Investigation·TypeRandomized controlled/clinical trial·DateJun 17, 2024